Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Meningococcus A, C, W135, Y vaccin

Generic name
Meningococcus A, C, W135, Y vaccin
Brand name
ATC Code
J07AH08

Pharmacokinetics in children

No information

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

NATIONAL VACCINATION PROGRAMME for meningococci ACWY
  • Intramuscular
    • 14 months
      [4]
      • 0.5 ml/dose, once only.
    • 14 years
      [4]
      • 2nd vaccination: 0.5 ml/dose, once only.
NeisVac-C: Vaccination against meningococcus C
  • Intramuscular
    • 2 months up to 4 months
      [1]
      • 0.5 ml/dose Vaccination schedule as follows:. 1 vaccination: any chosen time, irrespective of the age
        Second vaccination: at least 2 months after the first vaccination
        It is recommended that a booster dose should be given at the age of 12-13 months, with an interval of at least 6 months after the last vaccination.

        .

      • In infants, it should preferably be administered in the anterolateral side of the thigh.

    • 4 months up to 18 years
      [1]
      • 0.5 ml/dose, once only.
Nimenrix: Vaccination against invasive meningococcal diseases caused by Neisseria meningitidis groups A, C, W135 and Y.
  • Intramuscular
    • 6 weeks up to 12 weeks
      [2]
      • 0.5 ml/dose/dose Vaccination schedule as follows:. first vaccination: at age 6 weeks upwards
        second vaccination: 2 months after the first dose.
        Third vaccination: booster dose at the age of 12 months.
    • 1 year up to 18 years
      [2]
      • 0.5 ml/dose, once only.

      • A second dose after a period of 2 months can be considered for infants of 6-14 months with an elevated risk of meningococcal diseases based on exposure to W-135 and Y.

    • 12 weeks up to 1 year
      [5]
      • 0.5 ml/dose Vaccination schedule is as follows:. There is no approved vaccination scheme for children aged from 12 weeks to 1 year. According to the Dutch National Infectious Diseases Centre:
        2 doses with a two-month interval between them. If both doses were given before the age of 1 year, a third dose is given at the age of 14 months.

        .

      • According to the Standing Committee on Vaccination (STIKO), vaccination against meningococci of the ACWY serogroups is only recommended for certain indications/risk groups, which can be found in the current STIKO recommendations.[11]
Menveo: Vaccination against invasive meningococcal diseases caused by Neisseria meningitidis groups A, C, W135 and Y.
  • Intramuscular
    • 2 years up to 18 years
      [3]
      • 0.5 ml/dose, once only.
Bexsero: Vaccinatie tegen invasieve meningokokkenziekten veroorzaakt door Neisseria meningitidis-groepen B
  • Intramuscular
    • 2 months up to 3 months
      [6]
      • 0.5 ml/dose Vaccination schedule as follows:. 3 doses with an interval of at least 1 month; booster dose at the age of 12-15 months, at least 6 months after the primary series

        .
    • 3 months up to 6 months
      [6]
      • 0.5 ml/dose Vaccination schedule as follows:. > 2–5 months: 3 doses with an interval of at least 1 month; booster dose at the age of 12-15 months, at least 6 months after the primary series
        > 3–5 months:    2 doses with an interval of at least 2 months; booster dose at the age of 12-15 months, at least 6 months after the primary series.

        .
    • 6 months up to 24 months
      [6]
      • 0.5 ml/dose Vaccination schedule as follows:. 2 doses with an interval of at least 2 months. Booster dose:
        > 6-11 months:   Booster dose in the second year of life, at least 2 months after the primary series
        > 12-23 months: Booster dose 12-23 months after the primary series.

        .
    • ≥ 2 years
      [6]
      • 0.5 ml/dose Vaccination schedule as follows:. 2 doses with an interval of at least 1 month, no booster dose.
Vaccination against invasive meningococcal diseases caused by Neisseria meningitidis groups A, C, W135, Y
  • Intramuscular
    • ≥ 6 weeks
      [2] [3]

      • NIMENRIX
        Primary immunisation:
        6 weeks to 6 months:  2 doses (0,5 ml/dose) with an interval of 2 months
        6 months to 18  years: 1 dose (0,5 ml/dosis) 
        Boosterdose:
        In infants 6 weeks tot 12 months: 0,5 ml/dosis at 12 months, with a dosing interval of at least 2 months after the primary immunisation.

        MENVEO
        2 years to 18 years: 0.5 ml/dose, once.

        MENQUADFI
        12 months to 18 years: 0.5 ml/dose, once.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Very common (> 10%): fever, fatigue, drowsiness, irritability, headache, malaise. Muscle pain. Loss of appetite. Reaction at the injection site (pain, swelling; redness or a hardening of ≤ 5 cm).

Common (1-10%): gastrointestinal disturbances such as nausea, vomiting, diarrhea. Arthralgia. Chills. Skin rash. Hematoma at the injection site, hardening or redness of more than 5 cm.

Uncommon (0.1-1%): dizziness, hypoaesthesia. Insomnia, crying. Other reaction at injection site (induration, itching, warmth, numbness). Itching elsewhere, urticaria. Pain in the limbs.

Rare (0.01- 0.1%): lymphadenopathy. Fever convulsion.

Also reported: hypersensitivity (including anaphylaxis, bronchospasm, facial edema, angioedema). Tonic convulsion, syncope, paresthesia, hypotonia. Extensive swelling of the vaccinated limb, often with erythema and sometimes including a nearby joint, or swelling of the entire limb.

In children 12-23 months of age, also very common drowsiness.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

The vaccine does not protect against Neisseria meningitidis groups other than A, C, W135 and Y. Patients with immunodeficiency or who are being treated with immunosuppressants may show a reduced immunologic response or no immunologic response at all. Immunization with this vaccine does not replace standard immunization against diphtheria or tetanus.

With familial complement deficiencies (e.g., C5 or C3 deficiencies) or treatments that inhibit terminal complement activation (e.g., eculizumab), there is an increased risk of invasive disease by Neisseria meningitidis A, C, W135 and Y, even after antibody development after vaccination.

Consider booster vaccination if there is a particular risk of exposure to serogroup A and it has been more than approximately one year since a quadrivalent vaccine was administered. Decrease in bactericidal antibody titers against serogroup A has been reported; the clinical relevance of this is unknown.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Cholera vaccines
J07AE01
Haemophilus influenzae B vaccines
J07AG01
Meningococcal vaccines
J07AH09
J07AH07
Pertussis vaccines
J07AJ52
Pneumococcal vaccines
J07AL02
Tuberculosis vaccines
J07AN01
Typhoid vaccines
J07AP03
J07AP01

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

References

  1. Baxter Healthcare Ltd, SmPC NeisVac-C (RVG 26343) 30-005-2021, www.geneesmiddeleninformatiebank.nl
  2. Pfizer Europe MA EEIG, SmPC Nimenrix (EU/1/12/767/005-007) Rev 39; 16-10-2024, www.ema.europa.eu
  3. GSK Vaccines S.r.l, SmPC Menveo (EU/1/10/614/002-003) Rev 35. 26-08-24, www.ema.europa.eu
  4. RijksInstituut voor Volksgezondheid en Milieu (RIVM), Vaccinatie schema 2024, https://rijksvaccinatieprogramma.nl/vaccinaties/vaccinatieschema
  5. RijksInstituut voor Volksgezondheid en Milieu (RIVM), Richtlijn Rijksvaccinatieprogramma Uitvoering 2025., https://rijksvaccinatieprogramma.nl/professionals/richtlijnen/uitvoering, Vastgesteld 26 november 2024
  6. GSK Vaccines S.r.l, SmPC Bexsero (EU/1/12/812/001-4) 05-12-2018
  7. GlaxoSmithKline GmbH & Co. KG, SmPC Menjugate (PEI.H.02481.01.3)
  8. PFIZER PHARMA GmbH, SmPC Trumenba (EU/1/17/1187/001)
  9. Ständige Impfkommission (STIKO) beim Robert Koch-Institut (RKI), Empfehlungen der Ständigen Impfkommission (STIKO) - 2018/2019, Epidemiologisches Bulletin, 2018, 34, 335-382

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes